Early Ataluren Readthrough for Pediatric Nonsense-Mutation DMD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nonsense mutation Duchenne muscular dystrophy (nmDMD) leads to muscle damage and early death due to the loss of functional dystrophin protein, with existing treatments focusing on symptom management rather than addressing the underlying cause, and early intervention is critical to maintain functionality.
Innovation Solution
Administering ataluren, a compound that promotes ribosomal readthrough of premature stop codons, to pediatric patients aged 2 to 5 years, achieving a plasma concentration of 1-20 μg/mL, to restore dystrophin production and improve muscle function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ataluren is administered to pediatric patients aged 2-5 years, then dystrophin production is restored and muscle function is improved, but the disease progression cannot be completely halted
Solution Approach 1:
The patent applies preliminary action by initiating ataluren treatment early in the disease course (ages 2-5 years) before substantial muscle loss and fibrosis occur. This early intervention aims to restore dystrophin production during a critical window when muscle fibers are still relatively preserved, thereby maximizing the potential for functional improvement and delaying disease progression.
2Duration of action of moving object
If early intervention is implemented prior to substantial muscle loss, then functionality is maintained for longer, but treatment complexity and monitoring requirements increase
Solution Approach 1:
The patent incorporates feedback mechanisms through regular monitoring of muscle function using standardized assessments (such as the North Star Ambulatory Assessment) and measurement of dystrophin protein levels. This feedback allows clinicians to adjust treatment dosage and duration, optimize therapeutic outcomes, and identify patients who may require additional supportive therapies as the disease progresses.
3Reliability
If ataluren is administered at higher doses to maximize dystrophin restoration, then muscle function improvement is enhanced, but adverse effects and safety concerns increase
Solution Approach 1:
The patent applies parameter changes by carefully dosing ataluren based on patient age, weight, and disease severity. The recommended dosage ranges from 10-40 mg/kg/day, with adjustments made according to individual patient response and tolerance. This personalized dosing approach optimizes dystrophin restoration while minimizing adverse effects such as gastrointestinal disturbances and potential cardiac impacts.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ataluren effectively improves dystrophin expression and muscle function, delaying the progression of nmDMD symptoms, including loss of ambulation and cardiopulmonary issues, in pediatric patients.
Implementation Method 1
Ataluren promotes ribosomal readthrough of a premature stop codon in the DMD gene, enabling formation of full-length functional dystrophin protein
Data Source
AI summary
Provided herein is a method for ameliorating or managing nonsense mutation mediated Duchenne muscular dystrophy (nmDMD) in a pediatric patient in need thereof comprising, administering an effective amount of ataluren to the patient.